Sustained Safety and Efficacy of Once-Daily Hydromorphone Extended-Release (OROS® hydromorphone ER) Compared with Twice-Daily Oxycodone Controlled-Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain

Pain Practice

Volumn 13, Issue 1, 2013, Pages 30-40

  Richarz, Ute ^a   Waechter, Sandra ^a   Sabatowski, Rainer ^b   Szczepanski, Leszek ^c   Binsfeld, Heinrich ^d  

^a Janssen Cilag   (Switzerland)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Wyzsza Szkola Spoleczno Przyrodnicza   (Poland)

^d Schmerz Zentrum am St Franziskus Hospital   (Germany)

Author keywords

Chronic pain; Hydromorphone extended release; Long term safety; OROS; Sustained efficacy

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; OXYCODONE; PARACETAMOL;

ADULT; ANOREXIA; ARTICLE; CHRONIC PAIN; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 84871946892     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2012.00553.x     Document Type: Article

References (33)

1. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2006, with Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics. November 2006. DHHS Publication No. 2006-1232. Available from: http://www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed June 27, 2011.
2. US Census Bureau. Preliminary Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2010 (NST-PEST2010-01). 2002 estimate. Available from: http://www.census.gov/popest/research/eval-estimates/eval-es+2010.html. [last accessed April 4th, 2012].
3. Turk DC, Okifugi A. Pain terms and taxonomies of pain. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonica's Management of Pain. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2010:13-23.
4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
5. McCarberg BH, Nicholson BD, Todd KH, Palmer T, Penles L. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther. 2008;15:312-320.
6. Brennan MJ, Lieberman JA III. Sleep disturbances in patients with chronic pain: effectively managing opioid analgesia to improve outcomes. Curr Med Res Opin. 2009;25:1045-1055.
7. Shaiova L. The management of opioid-related sedation. Curr Pain Headache Rep. 2005;9:239-242.
8. Fine PG, Portenoy RK. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418-425.
9. Chou R, Fanciullo GJ, Fine PG, et al.Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
10. Kalso E, Allan L, Dellemijn PL, et al.Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7:381-386.
11. Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26:1505-1518.
12. Kaplan R, Parris WC, Citron ML, et al.Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol. 1998;16:3230-3237.
13. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426-439.
14. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;CD003447.
15. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage. 2003;25:169-178.
16. Drover DR, Angst MS, Valle M, et al.Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002;97:827-836.
17. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008;24:175-192.
18. Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R. A randomized study to demonstrate noninferiority of once-daily OROS(R) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract. 2010;10:404-415.
19. Hanna M, Thipphawong J. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008;7:17.
20. Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat Care. 2009;8:14.
21. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
22. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852-857.
23. Cherny NJ, Chang V, Frager G, et al.Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76:1283-1293.
24. Wallace M, Moulin DE, Rauck RL, et al.Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag. 2009;5:97-105.
25. Wallace M, Skowronski R, Khanna S, Tudor IC, Thipphawong J. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin. 2007;23:981-989.
26. Wallace M, Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med. 2010;11:1477-1488.
27. Mucci-LoRusso P, Berman BS, Silberstein PT, et al.Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain. 1998;2:239-249.
28. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol. 2001;41:500-506.
29. Koizumi W, Toma H, Watanabe K, et al.Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5mg tablets. Jpn J Clin Oncol. 2004;34:608-614.
30. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-78.
31. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60:927-934.
32. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005;6:21-28.
33. Bruera E, Belzile M, Pituskin E, et al.Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998;16:3222-3229.